2026 Poster Presentation Abstracts
POSTER #1: Accession - Clinical
A phase 1 study of ATTR-01, a novel oncolytic adenovirus targeting αvβ6 integrin, which expresses an anti-PD-L1 antibody in tumors following IV delivery in patients with selected epithelial cancers
Download the Full PDF Abstract
Download the Digital Poster
Watch the Video
POSTER #2: Accession - Preclinical
TROCEPT - A tumor-targeted precision immunovirotherapy enabling avb6 integrin-positive tumor-localized expression of an immune checkpoint inhibitor following intravenous delivery
Download the Full PDF Abstract
Download the Digital Poster
Watch the Video
POSTER #3: Center for Cancer Research, NIH
Combination of a poly ADP-ribose polymerase (PARP) inhibitor with a T cell receptor β chain–directed antibody fusion molecule in immune-excluded prostate tumor models
Download the Full PDF Abstract
Download the Digital Poster
POSTER #4: Ensoma
In vivo HSC engineering generates lineage-restricted, multiplexed CAR-M, NK, and T cells that mediate synergistic anti-tumor activity in pre-clinical models
Download the Full PDF Abstract
Download the Digital Poster
POSTER #5: BlueWhale Bio
Improved T-Cell Expansion, Viability, and Metabolic Fitness with Synecta™ Cell-Derived Nanoparticles Across Clinically Relevant Media Conditions
Download the Full PDF Abstract
Download the Digital Poster
POSTER #6: Novartis
Leveraging Donor-Derived, In-Vitro PBMC Assay to Model B cell Depletion and Test Efficacy of B Cell–Targeted Agents for Non-Hodgkin’s Lymphoma Indications
Download the Full PDF Abstract
Download the Digital Poster
POSTER #7: OncoPrecision
A first-in-class CD64-targeting ADC for the selective depletion of pathogenic monocytic cells in hematologic and solid tumors
Download the Full PDF Abstract
Download the Digital Poster
POSTER #8: Viska Bio
A First-in-Class Nanobody–Enzyme Platform for TME Reprogramming: Coupling EGFR-Targeted Cytotoxicity with Immunogenic Cell Death
Download the Full PDF Abstract
Download the Digital Poster